PMID- 29588611
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 1178-7066 (Print)
IS  - 1178-7066 (Electronic)
IS  - 1178-7066 (Linking)
VI  - 11
DP  - 2018
TI  - The utility of pharmacogenetic testing to support the treatment of bipolar 
      disorder.
PG  - 35-42
LID - 10.2147/PGPM.S160967 [doi]
AB  - BACKGROUND: Bipolar disorder (BD) is a frequent cause of disability, health care 
      costs, and risk of suicide. Pharmacogenetic tests (PGTs) could help clinicians to 
      identify those patients predisposed to the occurrence of adverse events (AEs) 
      improving the understanding of the correlation between genetic variants and drug 
      response. MATERIALS AND METHODS: The study evaluated 30 patients affected by BD 
      type I or II (according to Diagnostic and Statistical Manual of Mental Disorders, 
      version 5) who underwent the PGT Neurofarmagen((R)) (AB-BIOTICS SA, Barcelona, 
      Spain) between March 2016 and March 2017. The primary aim of this study was to 
      identify if the treatment prescribed by the psychiatrists was consistent with the 
      treatment suggested by the PGT at T0 (corresponding to the test report 
      communication). As a secondary aim, we wanted to assess if clinicians had changed 
      the treatment (in case of discordance) at T1 (3-month follow-up visit) according 
      to the results of the PGT. RESULTS: At T0, only 4 patients (13%) had an optimal 
      therapy in line with the PGT suggestions. At 3-month follow-up, 13 patients (40%) 
      had received a change of therapy consistent to the test, showing a significant 
      statistical improvement in the Clinical Global Impression item Severity (CGI-S) 
      score over time compared to those not having changes consistent with the test. 
      Regarding AEs, at baseline 9 out of 10 (90%) of the patients who received a 
      therapy modification according to the test presented AEs, and a significant 
      within-group reduction was observed after 3 months (p = 0.031). CONCLUSION: 
      Despite the small sample size, the study shows promising data about the 
      usefulness of PGT to support clinicians in reaching a more effective and 
      tolerated treatment in the routine approach of BD.
FAU - Ielmini, Marta
AU  - Ielmini M
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of 
      Insubria, Varese, Italy.
FAU - Poloni, Nicola
AU  - Poloni N
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of 
      Insubria, Varese, Italy.
FAU - Caselli, Ivano
AU  - Caselli I
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of 
      Insubria, Varese, Italy.
FAU - Espadaler, Jordi
AU  - Espadaler J
AD  - AB-BIOTICS S.A, R&D Unit, Sant Cugat del Valles, Barcelona, Spain.
FAU - Tuson, Miquel
AU  - Tuson M
AD  - AB-BIOTICS S.A, R&D Unit, Sant Cugat del Valles, Barcelona, Spain.
FAU - Grecchi, Alessandro
AU  - Grecchi A
AD  - ASST Santi Paolo e Carlo Borromeo, Division of Psychiatry, Milan, Italy.
FAU - Callegari, Camilla
AU  - Callegari C
AD  - Department of Medicine and Surgery, Division of Psychiatry, University of 
      Insubria, Varese, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180316
PL  - New Zealand
TA  - Pharmgenomics Pers Med
JT  - Pharmacogenomics and personalized medicine
JID - 101514107
PMC - PMC5860421
OTO - NOTNLM
OT  - adverse events
OT  - bipolar disorder
OT  - mood disorder
OT  - personalized medicine
OT  - pharmacogenetics
OT  - pharmacogenetics testing
OT  - tolerability
COIS- Disclosure JE and MT are employed by AB-BIOTICS, S.A. Cugat del Valles 
      (Barcelona). The other authors report no conflicts of interest in this work.
EDAT- 2018/03/29 06:00
MHDA- 2018/03/29 06:01
PMCR- 2018/03/16
CRDT- 2018/03/29 06:00
PHST- 2018/03/29 06:00 [entrez]
PHST- 2018/03/29 06:00 [pubmed]
PHST- 2018/03/29 06:01 [medline]
PHST- 2018/03/16 00:00 [pmc-release]
AID - pgpm-11-035 [pii]
AID - 10.2147/PGPM.S160967 [doi]
PST - epublish
SO  - Pharmgenomics Pers Med. 2018 Mar 16;11:35-42. doi: 10.2147/PGPM.S160967. 
      eCollection 2018.